NASDAQ: ATYRAtyr Pharma Inc Stock
$3.28+0.18 (+5.81%)
Updated Apr 21, 2025
ATYR Price
$3.28
Fair Value Price
-$0.03
Market Cap
$291.46M
52 Week Low
$1.42
52 Week High
$4.66
P/E
-3.81x
P/B
4.16x
P/S
1,143.94x
PEG
N/A
Dividend Yield
N/A
Revenue
$235.00k
Earnings
-$64.02M
Gross Margin
100%
Operating Margin
-27,243.83%
Profit Margin
-27,243.8%
Debt to Equity
0.39
Operating Cash Flow
-$69M
Beta
0.85
Next Earnings
Apr 30, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ATYR Overview
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ATYR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ATYR
Ranked#115 of 462
Ranked#115 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important ATYR news, forecast changes, insider trades & much more!
ATYR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATYR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATYR ($3.28) is overvalued by 10,274.59% relative to our estimate of its Fair Value price of -$0.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ATYR ($3.28) is not significantly undervalued (10,274.59%) relative to our estimate of its Fair Value price of -$0.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ATYR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATYR due diligence checks available for Premium users.
Valuation
ATYR fair value
Fair Value of ATYR stock based on Discounted Cash Flow (DCF)
Price
$3.28
Fair Value
-$0.03
Undervalued by
10,274.59%
ATYR ($3.28) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATYR ($3.28) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATYR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ATYR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.81x
Industry
-184.27x
Market
27.14x
ATYR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.16x
Industry
4.04x
ATYR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATYR's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.0M
Profit Margin
0%
ATYR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ATYR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$96.8M
Liabilities
$27.0M
Debt to equity
0.39
ATYR's short-term assets ($81.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATYR's short-term assets ($81.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATYR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATYR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.1M
Investing
-$6.1M
Financing
$18.8M
ATYR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATYR vs Biotech Stocks
Atyr Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.